Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2013

View Archived Issues

Serum albumin binding proteins developed at Ablynx

Serine racemase knockout mice show decreased susceptibility to seizures

Pharma Bio partners timodepressin in Russia

NanoSmart and UCLA collaborate on new drug delivery platform

Innate Pharma presents phase I results for their anti-KIR antibody in AML

Novel radiotracers for imaging tau pathology evaluated

New antineoplastic agents synthesized at Pharminox

French researchers disclose new monoclonal antibodies for cancer and other disorders

ArQule patents new protein kinase inhibitors for cancer

Enrollment in phase II GMI-1070 trial in sickle cell disease completed

Novel thrombin inhibitors divulged by Chinese researchers

Iluvien receives marketing approval for chronic diabetic macular edema in Spain

Scientists at Kissei Pharmaceutical synthesize new SGLT2 inhibitors

Xencor receives milestone payment from Janssen for Xtend antibody

Boehringer Ingelheim enrolls patients in phase III HCVerso program

Medicago signs loan agreement with major pharmaceutical company

Siemens presents early clinical results for [18F]-T-807

Kyorin and Daiichi Sankyo terminate imidafenacin agreement in Brazil

Emergent BioSolutions begins phase II trial of NuThrax anthrax vaccine

Data and safety monitoring board clears way to completion for SyNAPSe trial

European CHMP hands down negative opinion for Raxone MAA

FDA approves first patch for treatment of migraine

European CHMP set to discuss MAA for defibrotide

Omeros' CRA technology identifies small molecules for Class B GPCR

Phase I study of KPT-330 opens to patients with AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...